All In Biotech

Drug Trial Radar · NCT06400615

Study That Tests AD109 in Patients Taking GLP-1 Drugs

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 20, 2024

Primary completion

Dec 26, 2024

Study completion Dec 26, 2024

Sponsor

Lead sponsor
ApnimedIndustry
Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Conditions

  • OSA

Interventions

  • AD109Drug

    Oral administration at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objective (Adverse Events)Time frame: 6 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • Clinical Neuroscience Solutions, Inc

    Jacksonville, Florida

  • Monroe Biomedical Research

    Monroe, North Carolina

  • Clinical Neuroscience Solutions, Inc

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.